Publication details

Novorozenecký screening těžké kombinované imunodeficience (SCID) v České republice

Title in English Neonatal screening of severe combined immunodeficiency (SCID) in the Czech Republic
Authors

KLOCPERK Adam BLOOMFIELD Markéta SCHNEIDEROVÁ Helena HLAVÁČKOVÁ Eva TURNOVEC Marek TICHÝ Lukáš ČECH Zbyněk CHRASTINA Petr DVOŘÁKOVÁ Lenka PEŠKOVÁ Karolína FORMÁNKOVÁ Renata VLKOVÁ Marcela BEJDÁK Petr FROŇKOVÁ Eva KALINA Tomáš ŘÍČNÁ Dita GROMBIŘÍKOVÁ Hana BÍLY Viktor SEDLÁČEK Petr LITZMAN Jiří FREIBERGER Tomáš ŠEDIVÁ Anna

Year of publication 2024
Type Article in Periodical
Magazine / Source Alergie
MU Faculty or unit

Faculty of Medicine

Citation
Keywords screening, SCID, severe combined immunodeficiency, TREC, KREC
Description In the years 2022–2023, a pilot program was conducted in the Czech Republic to expand newborn screening to include testing for severe combined immunodeficiency (SCID) by quantifying TREC and KREC excision DNA molecules. Over 90% of newborns participated in the screening, and thus over the course of two years, 198 675 neonatal tests were performed. Two patients with SCID were diagnosed, one with CD3E deficiency and one with atypical complete DiGeorge syndrome, along with another 17 patients with various other non-SCID immuno- deficiencies. For those identified with SCID, early identification through the screening program allowed for prompt genetic diagnosis and the initiation of causal therapy with hematopoietic cell transplantation and thymus transplantation before reaching 4 months of age, thus improving their overall prognosis. For non-SCID patients, early identification enabled individualised outpatient monitoring, regimental measures, and prophylactic therapy, which minimised their subsequent morbidity. Due to its success, the SCID screening program was incorporated into the standard newborn screening in the Czech Republic from January 1, 2024.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info